<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Urol Ann</journal-id><journal-id journal-id-type="iso-abbrev">Urol Ann</journal-id><journal-id journal-id-type="publisher-id">UA</journal-id><journal-title-group><journal-title>Urology Annals</journal-title></journal-title-group><issn pub-type="ppub">0974-7796</issn><issn pub-type="epub">0974-7834</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28794594</article-id><article-id pub-id-type="pmc">5532895</article-id><article-id pub-id-type="publisher-id">UA-9-261</article-id><article-id pub-id-type="doi">10.4103/UA.UA_23_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tanuma</surname><given-names>Yasushi</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Yoshinori</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Takeyama</surname><given-names>Ko</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Okamoto</surname><given-names>Tomoshi</given-names></name><xref ref-type="aff" rid="aff4">3</xref></contrib></contrib-group><aff id="aff1">Department of Urology, Hokkaido Social Welfare Association Hakodate Hospital, Hakodate, Japan</aff><aff id="aff2"><label>1</label>Department of Urology, Hokkaido Prefectural Esashi Hospital, Esashi, Japan</aff><aff id="aff3"><label>2</label>Department of Urology, Hakodate National Hospital, Hakodate, Japan</aff><aff id="aff4"><label>3</label>Okamoto Urology Clinic, Hokkaido, Japan</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Yasushi Tanuma, Department of Urology, Hokkaido Social Welfare Association Hakodate Hospital, 4-6 Komaba-cho, Hakodate, Hokkaido 042-0935, Japan. E-mail: <email xlink:href="fuminuma@msc.ncv.ne.jp">fuminuma@msc.ncv.ne.jp</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2017</year></pub-date><volume>9</volume><issue>3</issue><fpage>261</fpage><lpage>267</lpage><history><date date-type="received"><day>02</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © 2017 Urology Annals</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3600" xml_f="3613" txt_i="11" txt_f="24">Introduction:</offsets></title><p><offsets xml_i="3624" xml_f="3810" txt_i="25" txt_f="211">We evaluated the predictive factors which affect the efficacy of naftopidil 50 mg/day therapy and dose increase therapy to administration of 75 mg/day after an initial dose of 50 mg/day.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3841" xml_f="3863" txt_i="213" txt_f="235">Materials and Methods:</offsets></title><p><offsets xml_i="3874" xml_f="4403" txt_i="236" txt_f="765">A total of 92 patients with male lower urinary tract symptoms/benign prostatic hyperplasia were administrated naftopidil 50 mg/day for 4 weeks (50 mg therapy). At week 4, the patients were divided into an effective and an ineffective group (Group E and Group I, respectively). For further 4 weeks, the dosage of naftopidil was increased to 75 mg/day in all patients. At week 8, the patients of Group E and Group I were divided into an effective and an ineffective group (Group EE, Group EI, Group IE, and Group II, respectively).</offsets></p></sec><sec id="st3"><title><offsets xml_i="4434" xml_f="4442" txt_i="767" txt_f="775">Results:</offsets></title><p><offsets xml_i="4453" xml_f="4865" txt_i="776" txt_f="1188">Postvoid residual (PVR) urine volume at baseline was a predictive factor for efficacy of 50 mg therapy. In Group E, change in International Prostate Symptom Score storage symptoms subscore from baseline to week 4 was a predictive factor for efficacy of this dose increase therapy. In Group I, change in maximum flow rate from baseline to week 4 was a predictive factor for efficacy of this dose increase therapy.</offsets></p></sec><sec id="st4"><title><offsets xml_i="4896" xml_f="4908" txt_i="1190" txt_f="1202">Conclusions:</offsets></title><p><offsets xml_i="4919" xml_f="5190" txt_i="1203" txt_f="1474">The short term of naftopidil 50 mg therapy was ineffective for the patients who had large PVR. The predictive factor of this dose increase therapy might be a dynamic variable in 50 mg/day of dose period, but not a baseline variable at the time of 75 mg/day dosage starts.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>Dose increase therapy</kwd><kwd>lower urinary tract symptoms/benign prostatic hyperplasia</kwd><kwd>naftopidil</kwd><kwd>predictive factor</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5476" xml_f="5488" txt_i="1483" txt_f="1495">INTRODUCTION</offsets></title><p><offsets xml_i="5499" xml_f="5817" txt_i="1496" txt_f="1814">It is necessary to evaluate the short-term efficacy of α1-adrenoceptor (AR) antagonist (α1-blockers; α1B) to relieve the patients from bother of male lower urinary tract symptoms/benign prostatic hyperplasia (mLUTS/BPH) immediately, and if the initial treatment is not improvement, the next strategy should be thought.</offsets></p><p><offsets xml_i="5824" xml_f="6115" txt_i="1815" txt_f="2106">Therefore, we evaluated following two points. First, the predictive factors which affect the efficacy of naftopidil 50 mg/day for 4 weeks (50 mg therapy) were evaluated. Second, the predictive factors which affect the efficacy of naftopidil dose increase to 75 mg/day therapy were evaluated.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="6178" xml_f="6199" txt_i="2108" txt_f="2129">MATERIALS AND METHODS</offsets></title><p><offsets xml_i="6210" xml_f="6465" txt_i="2130" txt_f="2385">In this study, the inclusion criteria were age ≥50 years, prostate volume (PV) ≥20 mL, International Prostate Symptom Score (IPSS) ≥8, and IPSS quality of life (IPSS-QoL) score ≥3. The patients with the previous medical therapy were included in the study.</offsets></p><p><offsets xml_i="6472" xml_f="6908" txt_i="2386" txt_f="2822">The exclusion criteria were patients who had prostatic cancer, urethral stricture, complications to influence on voiding function, high disease activity across the multiple organs, comprehension difficulties, and serious systemic condition. Moreover, the patients who are receiving other drugs affecting the urinary function were excluded. Patients judged by an attending physician to be inappropriate were also excluded from the study.</offsets></p><p><offsets xml_i="6915" xml_f="7094" txt_i="2823" txt_f="3002">The sample size was calculated as follows. It was reported that the average of change in IPSS and standard deviation by the treatment of naftopidil was 5.9 and 5.8, respectively.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="7127" xml_f="7128" txt_i="3002" txt_f="3003">1</offsets></xref><offsets xml_i="7135" xml_f="7403" txt_i="3003" txt_f="3271">] Therefore, 13 patients were necessary so that it is 5% of considerable levels and 90% of statistical power. It was reported that the ineffective rate of naftopidil was about 40% by evaluation of the Japanese Urological Association (JUA) clinical guidelines for BPH.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="7436" xml_f="7437" txt_i="3271" txt_f="3272">2</offsets></xref><xref rid="ref3" ref-type="bibr"><offsets xml_i="7477" xml_f="7478" txt_i="3272" txt_f="3273">3</offsets></xref><offsets xml_i="7485" xml_f="7566" txt_i="3273" txt_f="3354">] By these reports, we calculated that the necessary sample size was 81 patients.</offsets></p><p><offsets xml_i="7573" xml_f="7732" txt_i="3355" txt_f="3514">This study was approved by the Institutional Review Board of Hokkaido Social Welfare Association Hakodate Hospital and agreed to by all participating patients.</offsets></p><p><offsets xml_i="7739" xml_f="8144" txt_i="3515" txt_f="3920">Ninety-two patients diagnosed with clinical mLUTS/BPH from July 2006 to May 2013 were enrolled. Nine patients were withdrawn from participation, including two for nonadherence, one with prostate cancer, one who was visited another hospital by comorbidity, one who was not measured the objective findings, and four who failed to make follow-up visits. Thus, efficacy was analyzed in a total of 83 patients.</offsets></p><p><offsets xml_i="8151" xml_f="8468" txt_i="3921" txt_f="4238">Naftopidil was administered at an initial dose of 50 mg/day for 4 weeks and increased to 75 mg/day for further 4 weeks. Age and PV were evaluated at the start of treatment. IPSS, IPSS-QoL, voided volume, maximum flow rate (MFR), and postvoid residual (PVR) urine volume were evaluated at baseline, week 4, and week 8.</offsets></p><p><offsets xml_i="8475" xml_f="8573" txt_i="4239" txt_f="4337">The evaluation of efficacy was defined using the criteria in the JUA clinical guidelines for BPH.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="8606" xml_f="8607" txt_i="4337" txt_f="4338">3</offsets></xref><offsets xml_i="8614" xml_f="9452" txt_i="4338" txt_f="5173">] It was as follows. (1) The efficacy for symptom was classified by the ratio with post- and pre-treatment of IPSS as excellent: ≤0.25, good: ≤0.5, fair: ≤0.75, and poor/worse: &gt;0.75. (2) The efficacy for QoL was classified by the changes in pre- and post-treatment of IPSS-QoL as excellent: ≥4, good: 3, fair: 2 or 1, and poor/worse: ≤0. (3) The efficacy for function was classified by the changes in post- and pretreatment of MFR as excellent: ≥10 mL/s, good: ≥5 mL/s, fair: ≥2.5 mL/s, and poor/worse: ≤0.5 mL/s. (4) Overall efficacy is the median of efficacy grade of three items as symptom, QoL, and function. Moreover, the patients who were evaluated excellent, good, or fair by overall efficacy were judged effective group, and the patients who were evaluated poor/worse by overall efficacy were judged worse group in this study.</offsets></p><p><offsets xml_i="9459" xml_f="9966" txt_i="5174" txt_f="5681">At week 4, the patients were divided into an effective and an ineffective group in 50 mg therapy (Group E and Group I, respectively). For further 4 weeks, the dosage of naftopidil was increased to 75 mg/day in all patients. At week 8, the patients in Group E were divided into an effective and an ineffective group in this dose increase therapy (Group EE and Group EI, respectively). The patients in Group I were divided into an effective and an ineffective group, too (Group IE and Group II, respectively).</offsets></p><p><offsets xml_i="9973" xml_f="10021" txt_i="5682" txt_f="5730">The intragroup data were analyzed by the paired </offsets><italic><offsets xml_i="10029" xml_f="10030" txt_i="5730" txt_f="5731">t</offsets></italic><offsets xml_i="10039" xml_f="10129" txt_i="5731" txt_f="5821">-test or the Wilcoxon signed-rank test. The intergroup data were analyzed by the unpaired </offsets><italic><offsets xml_i="10137" xml_f="10138" txt_i="5821" txt_f="5822">t</offsets></italic><offsets xml_i="10147" xml_f="10935" txt_i="5822" txt_f="6610">-test or the Mann–Whitney U-test. The Logistic-regression analysis was used to identify the predictive factors. The effective and ineffective groups were applied as a dependent variable. IPSS-QoL, MFR, and PVR were applied as an independent variable. To avoid any confounding, only three subjective symptom scores of IPSS post-micturition symptoms subscore (incomplete emptying; IPSS PMS), IPSS storage symptoms subscore (frequency, urgency, and nocturia; IPSS-SS), and IPSS voiding symptoms subscore (intermittency, weak stream, and straining; IPSS-VS) were applied as an independent variable. This independent variable at week 4 and the amount of change from baseline to week 4 were defined as the baseline variable and the dynamic variable of this dose increase therapy, respectively. </offsets><italic><offsets xml_i="10943" xml_f="10944" txt_i="6610" txt_f="6611">P</offsets></italic><offsets xml_i="10953" xml_f="11005" txt_i="6611" txt_f="6660"> &lt; 0.05 was considered statistically significant.</offsets></p></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="11058" xml_f="11065" txt_i="6662" txt_f="6669">RESULTS</offsets></title><sec id="sec2-1"><title><offsets xml_i="11097" xml_f="11151" txt_i="6670" txt_f="6724">Distribution of the group and baseline characteristics</offsets></title><p><offsets xml_i="11162" xml_f="11592" txt_i="6725" txt_f="7155">Forty six patients (55.4%) were effective (Group E), and 37 patients (44.6%) were ineffective (Group I) in 50 mg/day therapy for 4 weeks. In Group E, 38 patients (45.8%) were effective (Group EE), and 8 patients (9.6%) were ineffective (Group EI) in the dose increase therapy for 8 weeks. In Group I, 17 patients (20.5%) were effective (Group IE), and 20 patients (24.1%) were ineffective (Group II) in the dose increase therapy [</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="11622" xml_f="11630" txt_i="7155" txt_f="7163">Figure 1</offsets></xref><offsets xml_i="11637" xml_f="11731" txt_i="7163" txt_f="7257">]. In this dose increase therapy, 55 patients (66.3%) showed improvement of overall efficacy [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="11763" xml_f="11770" txt_i="7257" txt_f="7264">Table 1</offsets></xref><offsets xml_i="11777" xml_f="11884" txt_i="7264" txt_f="7371">]. Only PVR in baseline characteristics was significantly larger in the Group I compared with the Group E [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="11916" xml_f="11923" txt_i="7371" txt_f="7378">Table 2</offsets></xref><offsets xml_i="11930" xml_f="11932" txt_i="7378" txt_f="7380">].</offsets></p><fig id="F1" position="float"><label><offsets xml_i="11973" xml_f="11981" txt_i="7381" txt_f="7389">Figure 1</offsets></label><caption><p><offsets xml_i="12001" xml_f="12461" txt_i="7389" txt_f="7849">Distribution of patients. The patients were divided into four groups which were effective and ineffective. The evaluation of efficacy was defined using the criteria in the Japanese Urological Association clinical guidelines for benign prostatic hyperplasia. The patients who were evaluated excellent, good, or fair by overall efficacy were judged effective group, and the patients who were evaluated poor/worse by overall efficacy were judged ineffective group</offsets></p></caption><graphic xlink:href="UA-9-261-g001"></graphic></fig><table-wrap id="T1" position="float"><label><offsets xml_i="12571" xml_f="12578" txt_i="7850" txt_f="7857">Table 1</offsets></label><caption><p><offsets xml_i="12598" xml_f="12715" txt_i="7857" txt_f="7974">Evaluation of efficacy using the Japanese Urological Association clinical guidelines for benign prostatic hyperplasia</offsets></p></caption><graphic xlink:href="UA-9-261-g002"></graphic></table-wrap><table-wrap id="T2" position="float"><label><offsets xml_i="12832" xml_f="12839" txt_i="7975" txt_f="7982">Table 2</offsets></label><caption><p><offsets xml_i="12859" xml_f="12883" txt_i="7982" txt_f="8006">Baseline characteristics</offsets></p></caption><graphic xlink:href="UA-9-261-g003"></graphic></table-wrap></sec><sec id="sec2-2"><title><offsets xml_i="12986" xml_f="13053" txt_i="8008" txt_f="8075">The predictive factors which affected the efficacy of 50 mg therapy</offsets></title><p><offsets xml_i="13064" xml_f="13237" txt_i="8076" txt_f="8249">Groups E and I were applied as the dependent variable. The predictive factor which affected the efficacy of 50 mg therapy was large PVR at baseline [odds ratio (OR): 1.013, </offsets><italic><offsets xml_i="13245" xml_f="13246" txt_i="8249" txt_f="8250">P</offsets></italic><offsets xml_i="13255" xml_f="13265" txt_i="8250" txt_f="8260"> = 0.012, </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="13295" xml_f="13303" txt_i="8260" txt_f="8268">Figure 2</offsets></xref><offsets xml_i="13310" xml_f="13494" txt_i="8268" txt_f="8452">]. All parameters of change in subjective symptoms and objective findings, except MFR at week 8 and PVR at weeks 4 and 8, were significantly improved in Group E compared with Group I [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="13526" xml_f="13533" txt_i="8452" txt_f="8459">Table 3</offsets></xref><offsets xml_i="13540" xml_f="13542" txt_i="8459" txt_f="8461">].</offsets></p><fig id="F2" position="float"><label><offsets xml_i="13583" xml_f="13591" txt_i="8462" txt_f="8470">Figure 2</offsets></label><caption><p><offsets xml_i="13611" xml_f="13775" txt_i="8470" txt_f="8634">The predictive factors which affected the efficacy of 50 mg/day for 4 weeks. The Logistic-regression analysis was used to identify the predictive factors. Group E (</offsets><italic><offsets xml_i="13783" xml_f="13784" txt_i="8634" txt_f="8635">n</offsets></italic><offsets xml_i="13793" xml_f="13813" txt_i="8635" txt_f="8655"> = 46) and Group I (</offsets><italic><offsets xml_i="13821" xml_f="13822" txt_i="8655" txt_f="8656">n</offsets></italic><offsets xml_i="13831" xml_f="13992" txt_i="8656" txt_f="8817"> = 37) were applied as a dependent variable. The predictive factor was large PVR at baseline. Closed circle: Odds ratio, horizontal line: 95% confidence interval</offsets></p></caption><graphic xlink:href="UA-9-261-g004"></graphic></fig><table-wrap id="T3" position="float"><label><offsets xml_i="14102" xml_f="14109" txt_i="8818" txt_f="8825">Table 3</offsets></label><caption><p><offsets xml_i="14129" xml_f="14203" txt_i="8825" txt_f="8899">Change in subjective symptoms and objective findings (Group E and Group I)</offsets></p></caption><graphic xlink:href="UA-9-261-g005"></graphic></table-wrap></sec><sec id="sec2-3"><title><offsets xml_i="14306" xml_f="14392" txt_i="8901" txt_f="8987">The predictive factors which affected the efficacy of dose increase therapy in Group E</offsets></title><p><offsets xml_i="14403" xml_f="14657" txt_i="8988" txt_f="9242">When Groups EE and EI were applied as the dependent variable and the baseline variables at the time of 75 mg/day dosage starts were applied as the independent variable, there was no predictive factor which affected the efficacy of dose increase therapy [</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="14687" xml_f="14696" txt_i="9242" txt_f="9251">Figure 3a</offsets></xref><offsets xml_i="14703" xml_f="14982" txt_i="9251" txt_f="9530">]. On the other hand, when the dynamic variables that were the amount of change from baseline to week 4 were applied as the independent variable, the predictive factor which affected the efficacy of dose increase therapy was change in IPSS-SS from baseline to week 4 [OR: 2.137, </offsets><italic><offsets xml_i="14990" xml_f="14991" txt_i="9530" txt_f="9531">P</offsets></italic><offsets xml_i="15000" xml_f="15010" txt_i="9531" txt_f="9541"> = 0.024, </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="15040" xml_f="15049" txt_i="9541" txt_f="9550">Figure 3b</offsets></xref><offsets xml_i="15056" xml_f="15058" txt_i="9550" txt_f="9552">].</offsets></p><fig id="F3" position="float"><label><offsets xml_i="15099" xml_f="15107" txt_i="9553" txt_f="9561">Figure 3</offsets></label><caption><p><offsets xml_i="15127" xml_f="15304" txt_i="9561" txt_f="9738">The predictive factors which affected the efficacy of dose increase therapy in Group E. The Logistic-regression analysis was used to identify the predictive factors. Groups EE (</offsets><italic><offsets xml_i="15312" xml_f="15313" txt_i="9738" txt_f="9739">n</offsets></italic><offsets xml_i="15322" xml_f="15335" txt_i="9739" txt_f="9752">=38) and EI (</offsets><italic><offsets xml_i="15343" xml_f="15344" txt_i="9752" txt_f="9753">n</offsets></italic><offsets xml_i="15353" xml_f="15727" txt_i="9753" txt_f="10127">=8) were applied as the dependent variable. (a) The baseline variables at the time of 75 mg/day dosage starts were applied as the independent variable. There was no predictive factor. (b) The dynamic variables that were the amount of change from baseline to week 4 were applied as the independent variable. The predictive factor was change in IPSS-SS from baseline to week 4</offsets></p></caption><graphic xlink:href="UA-9-261-g006"></graphic></fig></sec><sec id="sec2-4"><title><offsets xml_i="15823" xml_f="15909" txt_i="10129" txt_f="10215">The predictive factors which affected the efficacy of dose increase therapy in Group I</offsets></title><p><offsets xml_i="15920" xml_f="16174" txt_i="10216" txt_f="10470">When Groups IE and II were applied as the dependent variable and the baseline variables at the time of 75 mg/day dosage starts were applied as the independent variable, there was no predictive factor which affected the efficacy of dose increase therapy [</offsets><xref ref-type="fig" rid="F4"><offsets xml_i="16204" xml_f="16213" txt_i="10470" txt_f="10479">Figure 4a</offsets></xref><offsets xml_i="16220" xml_f="16495" txt_i="10479" txt_f="10754">]. On the other hand, when the dynamic variables that were the amount of change from baseline to week 4 were applied as the independent variable, the predictive factor which affected the efficacy of dose increase therapy was change in MFR from baseline to week 4 [OR: 0.817, </offsets><italic><offsets xml_i="16503" xml_f="16504" txt_i="10754" txt_f="10755">P</offsets></italic><offsets xml_i="16513" xml_f="16523" txt_i="10755" txt_f="10765"> = 0.045, </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="16553" xml_f="16562" txt_i="10765" txt_f="10774">Figure 4b</offsets></xref><offsets xml_i="16569" xml_f="16571" txt_i="10774" txt_f="10776">].</offsets></p><fig id="F4" position="float"><label><offsets xml_i="16612" xml_f="16620" txt_i="10777" txt_f="10785">Figure 4</offsets></label><caption><p><offsets xml_i="16640" xml_f="16817" txt_i="10785" txt_f="10962">The predictive factors which affected the efficacy of dose increase therapy in Group I. The Logistic-regression analysis was used to identify the predictive factors. Groups IE (</offsets><italic><offsets xml_i="16825" xml_f="16826" txt_i="10962" txt_f="10963">n</offsets></italic><offsets xml_i="16835" xml_f="16848" txt_i="10963" txt_f="10976">=17) and II (</offsets><italic><offsets xml_i="16856" xml_f="16857" txt_i="10976" txt_f="10977">n</offsets></italic><offsets xml_i="16866" xml_f="17237" txt_i="10977" txt_f="11348">=20) were applied as the dependent variable. (a) The baseline variables at the time of 75 mg/day dosage starts were applied as the independent variable. There was no predictive factor. (b) The dynamic variables that were the amount of change from baseline to week 4 were applied as the independent variable. The predictive factor was change in MFR from baseline to week 4</offsets></p></caption><graphic xlink:href="UA-9-261-g007"></graphic></fig></sec></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="17361" xml_f="17371" txt_i="11351" txt_f="11361">DISCUSSION</offsets></title><p><offsets xml_i="17382" xml_f="17735" txt_i="11362" txt_f="11715">The treatment for mLUTS/BPH including in α1B is important to relieve the patients from bother immediately. Therefore, it is necessary to know the predictive factors which affect the efficacy of short-term α1B therapy. However, there were few reports about the predictive factors of short-term α1B therapy though there were some long-term reports of it.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="17768" xml_f="17769" txt_i="11715" txt_f="11716">4</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="17809" xml_f="17810" txt_i="11716" txt_f="11717">5</offsets></xref><xref rid="ref6" ref-type="bibr"><offsets xml_i="17850" xml_f="17851" txt_i="11717" txt_f="11718">6</offsets></xref><offsets xml_i="17858" xml_f="17859" txt_i="11718" txt_f="11719">]</offsets></p><p><offsets xml_i="17866" xml_f="17984" txt_i="11720" txt_f="11838">α1D/A-AR antagonist, naftopidil, was recommended to “highly recommended to do” in the JUA clinical guidelines for BPH[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="18017" xml_f="18018" txt_i="11838" txt_f="11839">3</offsets></xref><offsets xml_i="18025" xml_f="18105" txt_i="11839" txt_f="11919">] and is widely used for mLUTS/BPH treatment in Japan, Korea, China, and India.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="18138" xml_f="18139" txt_i="11919" txt_f="11920">7</offsets></xref><offsets xml_i="18146" xml_f="18218" txt_i="11920" txt_f="11992">] The standard dose of naftopidil is recommended with 50 and 75 mg/day;[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="18251" xml_f="18252" txt_i="11992" txt_f="11993">8</offsets></xref><offsets xml_i="18259" xml_f="18329" txt_i="11993" txt_f="12063">] many reports choose 50 mg/day of naftopidil for a maintenance dose.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="18362" xml_f="18363" txt_i="12063" txt_f="12064">9</offsets></xref><offsets xml_i="18370" xml_f="18518" txt_i="12064" txt_f="12212">] Recently, the efficacy of naftopidil dose increase therapy from 50 to 75 mg/day was evaluated for the patients who were ineffective in 50 mg/day.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="18552" xml_f="18554" txt_i="12212" txt_f="12214">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="18595" xml_f="18597" txt_i="12214" txt_f="12216">11</offsets></xref><offsets xml_i="18604" xml_f="18983" txt_i="12216" txt_f="12595">] However, it is unknown about the predictive factors which affect the efficacy of naftopidil dose increase therapy. Hence, we examined the predictive factors which affect the efficacy of naftopidil short-term therapy and dose increase therapy. In this study, it was the characteristic that the predictive factors were evaluated by the baseline variable and the dynamic variable.</offsets></p><p><offsets xml_i="18990" xml_f="19172" txt_i="12596" txt_f="12778">Overall efficacy rate of 50 mg therapy is 55.4% in this study. There were some reports that the effective ratio of naftopidil monotherapy for 8∼12 weeks were 50.8%, 52.5% and 68.6%.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="19206" xml_f="19208" txt_i="12778" txt_f="12780">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="19249" xml_f="19251" txt_i="12780" txt_f="12782">11</offsets></xref><xref rid="ref12" ref-type="bibr"><offsets xml_i="19292" xml_f="19294" txt_i="12782" txt_f="12784">12</offsets></xref><offsets xml_i="19301" xml_f="19382" txt_i="12784" txt_f="12865">] Therefore, it thought that this result was appropriate. Nevertheless, Mizusawa </offsets><italic><offsets xml_i="19390" xml_f="19395" txt_i="12865" txt_f="12870">et al</offsets></italic><offsets xml_i="19404" xml_f="19495" txt_i="12870" txt_f="12961">. reported that the effective ratio of naftopidil for 4 weeks of administration was 23.9%.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="19529" xml_f="19531" txt_i="12961" txt_f="12963">13</offsets></xref><offsets xml_i="19538" xml_f="19811" txt_i="12963" txt_f="13236">] They decided the responders using original questionnaire of treatment satisfaction. On the other hand, we decided the responders using the criteria of the JUA clinical guidelines for BPH in this study. Hence, these should not compare these reports with this study simply.</offsets></p><p><offsets xml_i="19818" xml_f="20090" txt_i="13237" txt_f="13509">Large PVR at baseline was a predictive factor which affected the efficacy of 50 mg therapy. IPSS and PVR at baseline were predictive factors of symptom progression in the Alfuzosin Long-Term Efficacy and Safety Study for 2 years which compared alfuzosin with the placebo.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="20124" xml_f="20126" txt_i="13509" txt_f="13511">14</offsets></xref><offsets xml_i="20133" xml_f="20143" txt_i="13511" txt_f="13521">] Kawachi </offsets><italic><offsets xml_i="20151" xml_f="20156" txt_i="13521" txt_f="13526">et al</offsets></italic><offsets xml_i="20165" xml_f="20347" txt_i="13526" txt_f="13708">. reported that the treatment failure rate of α1B for 4 years was affected by PV, PVR, history of acute urinary retention, and complications of overactive bladder (OAB) at baseline.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="20381" xml_f="20383" txt_i="13708" txt_f="13710">15</offsets></xref><offsets xml_i="20390" xml_f="20653" txt_i="13710" txt_f="13973">] PVR at baseline is a predictive factor for not only the long-term treatment but also the short-term treatment of α1B. Therefore, the patients with large PVR should choose the treatment except 50 mg therapy or combination with the drug that has other mechanisms.</offsets></p><p><offsets xml_i="20660" xml_f="20863" txt_i="13974" txt_f="14177">PV at baseline was not a predictive factor for the efficacy of 50 mg therapy in this study. There are some reports that patients with a larger PV have a higher risk of long-term α1B monotherapy failure.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="20896" xml_f="20897" txt_i="14177" txt_f="14178">4</offsets></xref><xref rid="ref5" ref-type="bibr"><offsets xml_i="20937" xml_f="20938" txt_i="14178" txt_f="14179">5</offsets></xref><xref rid="ref6" ref-type="bibr"><offsets xml_i="20978" xml_f="20979" txt_i="14179" txt_f="14180">6</offsets></xref><offsets xml_i="20986" xml_f="21087" txt_i="14180" txt_f="14281">] There were the reports that baseline PV did not affect the efficacy of the short-term α1B therapy.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="21121" xml_f="21123" txt_i="14281" txt_f="14283">12</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="21164" xml_f="21166" txt_i="14283" txt_f="14285">16</offsets></xref><offsets xml_i="21173" xml_f="21357" txt_i="14285" txt_f="14466">] Furthermore, we reported that the improvement of IPSS, IPSS-QoL, and MFR did not have a difference in large PV group (PV ≥40 mL) and small PV group (PV &lt;40 mL) for 50 mg therapy.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="21391" xml_f="21393" txt_i="14466" txt_f="14468">17</offsets></xref><offsets xml_i="21400" xml_f="21526" txt_i="14468" txt_f="14594">] PV at baseline might be a predictive factor for efficacy of the long-term treatment but not the short-term treatment of α1B.</offsets></p><p><offsets xml_i="21533" xml_f="21740" txt_i="14595" txt_f="14802">In Group E, there was no predictive factor in baseline variables, and the amount of change from baseline to week 4 in IPSS-SS might be a predictive factor for the efficacy of 75 mg/day dose increase therapy.</offsets></p><p><offsets xml_i="21747" xml_f="21870" txt_i="14803" txt_f="14926">There is a report that 45% of mLUTS/BPH patients had both bladder outlet obstruction (BOO) and detrusor overactivity (DO).[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="21904" xml_f="21906" txt_i="14926" txt_f="14928">18</offsets></xref><offsets xml_i="21913" xml_f="22109" txt_i="14928" txt_f="15124">] BOO was associated with DO by various factors such as ischemia, and DO is a frequent cause of OAB symptoms. However, there is a report that BOO and OAB may be caused independently in mLUTS/BPH.[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="22143" xml_f="22145" txt_i="15124" txt_f="15126">19</offsets></xref><offsets xml_i="22152" xml_f="22262" txt_i="15126" txt_f="15236">] Higher IPSS-SS score suggests OAB. Naftopidil has a higher affinity for α1D-AR subtype than α1A-AR subtype.[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="22296" xml_f="22298" txt_i="15236" txt_f="15238">20</offsets></xref><offsets xml_i="22305" xml_f="22355" txt_i="15238" txt_f="15288">] α1D-AR subtype regulated the bladder functions,[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="22389" xml_f="22391" txt_i="15288" txt_f="15290">21</offsets></xref><xref rid="ref22" ref-type="bibr"><offsets xml_i="22432" xml_f="22434" txt_i="15290" txt_f="15292">22</offsets></xref><offsets xml_i="22441" xml_f="22572" txt_i="15292" txt_f="15423">] and there was a report that naftopidil is particularly effective for storage symptoms (SSs) by the inhibition of α1D-AR subtype.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="22605" xml_f="22606" txt_i="15423" txt_f="15424">9</offsets></xref><offsets xml_i="22613" xml_f="23004" txt_i="15424" txt_f="15815">] Hence, in the patients who were ineffective in IPSS-SS by naftopidil, it is suggested that a cause of the SSs might be other factors independent of bladder function regulated by α1D-AR subtype. The patients that IPSS-SS was ineffective by 50 mg therapy might need to change it into other treatments. However, a large-scale study is necessary because the sample size is small in this study.</offsets></p><p><offsets xml_i="23011" xml_f="23342" txt_i="15816" txt_f="16147">In Group I, there was no predictive factor in the baseline variables, and the amount of change from baseline to week 4 in MFR might be a predictive factor in the dynamic variable which affected the efficacy of 75 mg/day dose increase therapy. However, the sample size is small in Groups IE and II. It is a limitation in this study.</offsets></p><p><offsets xml_i="23349" xml_f="23686" txt_i="16148" txt_f="16485">It is interesting that the predictive factors of this dose increase therapy were the dynamic variables, but not the baseline variables. There is a report that improvement of IPSS, IPSS-VS, urgency, and slow stream was already shown at the dose of 50 mg/day in the patients who were effective after naftopidil dose increase to 75 mg/day.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="23720" xml_f="23722" txt_i="16485" txt_f="16487">11</offsets></xref><offsets xml_i="23729" xml_f="23969" txt_i="16487" txt_f="16727">] This report showed that the predictive factors were the dynamic variables like this study. Therefore, the prediction of efficacy for dose increase therapy should pay attention to the dynamic variable in the treatment during 50 mg therapy.</offsets></p></sec><sec sec-type="conclusions" id="sec1-5"><title><offsets xml_i="24026" xml_f="24037" txt_i="16729" txt_f="16740">CONCLUSIONS</offsets></title><p><offsets xml_i="24048" xml_f="24259" txt_i="16741" txt_f="16952">We showed that large PVR at baseline was a predictive factor which affected the efficacy of 50 mg therapy. The short-term efficacy of 50 mg therapy was ineffective for the patients who had large PVR at baseline.</offsets></p><p><offsets xml_i="24266" xml_f="24665" txt_i="16953" txt_f="17352">The predictive factor of this dose increase therapy might be a dynamic variable in 50 mg/day of dose period, but not a baseline variable at the time of 75 mg/day dosage starts. Therefore, if dose increase to 75 mg/day was considered, it should not be judged from baseline variables at the start of 75 mg/day dosage starts and should be judged by the change of variables during 50 mg therapy periods.</offsets></p><sec id="sec2-5"><title><offsets xml_i="24693" xml_f="24726" txt_i="17353" txt_f="17386">Financial support and sponsorship</offsets></title><p><offsets xml_i="24737" xml_f="24741" txt_i="17387" txt_f="17391">Nil.</offsets></p></sec><sec id="sec2-6" sec-type="COI-statement"><title><offsets xml_i="24800" xml_f="24821" txt_i="17393" txt_f="17414">Conflicts of interest</offsets></title><p><offsets xml_i="24832" xml_f="24867" txt_i="17415" txt_f="17450">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>M</given-names></name><name><surname>Kamihira</surname><given-names>O</given-names></name><name><surname>Kinukawa</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Ohshima</surname><given-names>S</given-names></name><name><surname>Origasa</surname><given-names>H</given-names></name></person-group><article-title>Tokai Urological Clinical Trial Group. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial</article-title><source>BJU Int</source><year>2005</year><volume>96</volume><fpage>581</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16104914</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakisaki</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Moriya</surname><given-names>K</given-names></name><name><surname>Ameda</surname><given-names>K</given-names></name><name><surname>Shinno</surname><given-names>Y</given-names></name><name><surname>Togashi</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The effectiveness of anftopidil on the treatment of symptomatic benign prostatic hyperplasia</article-title><source>Jpn J Urol Surg</source><year>2005</year><volume>18</volume><fpage>825</fpage><lpage>31</lpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>Y</given-names></name><name><surname>Gotoh</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>O</given-names></name><name><surname>Masumori</surname><given-names>N</given-names></name><name><surname>Kawauchi</surname><given-names>A</given-names></name><name><surname>Yamanishi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Outline of JUA clinical guidelines for benign prostatic hyperplasia</article-title><source>Int J Urol</source><year>2011</year><volume>18</volume><fpage>741</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">22050351</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Rosette</surname><given-names>JJ</given-names></name><name><surname>Kortmann</surname><given-names>BB</given-names></name><name><surname>Rossi</surname><given-names>C</given-names></name><name><surname>Sonke</surname><given-names>GS</given-names></name><name><surname>Floratos</surname><given-names>DL</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name></person-group><article-title>Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms</article-title><source>J Urol</source><year>2002</year><volume>167</volume><fpage>1734</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11912399</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>SJ</given-names></name><name><surname>Ko</surname><given-names>WJ</given-names></name><name><surname>Kim</surname><given-names>SI</given-names></name><name><surname>Chung</surname><given-names>BH</given-names></name></person-group><article-title>Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: An observational cohort study</article-title><source>Eur Urol</source><year>2003</year><volume>44</volume><fpage>94</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12814681</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>KP</given-names></name><name><surname>Byun</surname><given-names>YJ</given-names></name><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>YY</given-names></name><name><surname>Chung</surname><given-names>WS</given-names></name></person-group><article-title>Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia</article-title><source>Korean J Urol</source><year>2010</year><volume>51</volume><fpage>488</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">20664783</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuta</surname><given-names>F</given-names></name><name><surname>Masumori</surname><given-names>N</given-names></name></person-group><article-title>A review of naftopidil for treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia</article-title><source>Curr Bladder Dysfunct Rep</source><year>2015</year><volume>10</volume><fpage>1690</fpage><lpage>9</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masumori</surname><given-names>N</given-names></name></person-group><article-title>Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia</article-title><source>Ther Clin Risk Manag</source><year>2011</year><volume>7</volume><fpage>227</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">21753885</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>Y</given-names></name><name><surname>Masue</surname><given-names>T</given-names></name><name><surname>Miwa</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Deguchi</surname><given-names>T</given-names></name></person-group><article-title>Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study</article-title><source>BJU Int</source><year>2006</year><volume>97</volume><fpage>747</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16536766</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Osanai</surname><given-names>H</given-names></name><name><surname>Numata</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Kakizaki</surname><given-names>H</given-names></name></person-group><article-title>α</article-title><source>Int J Urol</source><year>2013</year><volume>20</volume><fpage>513</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23078534</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funahashi</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>R</given-names></name><name><surname>Matsukawa</surname><given-names>Y</given-names></name><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Sassa</surname><given-names>N</given-names></name><name><surname>Gotoh</surname><given-names>M</given-names></name></person-group><article-title>Clinical effectiveness of a loading dose of naftopidil for patients with benign prostatic hyperplasia</article-title><source>World J Urol</source><year>2011</year><volume>29</volume><fpage>225</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20309563</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funahashi</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>R</given-names></name><name><surname>Yoshino</surname><given-names>Y</given-names></name><name><surname>Matsukawa</surname><given-names>Y</given-names></name><name><surname>Sassa</surname><given-names>N</given-names></name><name><surname>Gotoh</surname><given-names>M</given-names></name></person-group><article-title>Symptoms predictive for efficacy of naftopidil in patients with benign prostate hyperplasia</article-title><source>Low Urin Tract Symptoms</source><year>2011</year><volume>3</volume><fpage>113</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">26676397</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizusawa</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>N</given-names></name><name><surname>Obara</surname><given-names>K</given-names></name><name><surname>Isahaya</surname><given-names>E</given-names></name><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name></person-group><article-title>Clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms: A prospective study</article-title><source>Adv Urol</source><year>2011</year><volume>2011</volume><fpage>804583</fpage><pub-id pub-id-type="pmid">21603217</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roehrborn</surname><given-names>CG</given-names></name></person-group><article-title>ALTESS Study Group. Alfuzosin 10 mg once daily prevents BPH overall clinical progression but not acute urinary retention occurrence: Results of a 2-year placebo controlled study</article-title><source>BJU Int</source><year>2006</year><volume>97</volume><fpage>734</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16536764</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawachi</surname><given-names>Y</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Sugimura</surname><given-names>S</given-names></name><name><surname>Iwata</surname><given-names>S</given-names></name><name><surname>Noto</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: A pilot study comparing naftopidil and tamsulosin hydrochloride</article-title><source>Scand J Urol Nephrol</source><year>2010</year><volume>44</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">20095868</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masumori</surname><given-names>N</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Horia</surname><given-names>H</given-names></name><name><surname>Sunaoshi</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Takeyama</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Does baseline prostate volume affect the short-term outcome of Tamsulosin?</article-title><source>Low Urin Tract Symptoms</source><year>2014</year><volume>6</volume><fpage>113</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">26663551</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanuma</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Takeyama</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>T</given-names></name></person-group><article-title>Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?</article-title><source>Urol Ann</source><year>2016</year><volume>8</volume><fpage>20</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">26834396</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knutson</surname><given-names>T</given-names></name><name><surname>Edlund</surname><given-names>C</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><name><surname>Dahlstrand</surname><given-names>C</given-names></name></person-group><article-title>BPH with coexisting overactive bladder dysfunction – An everyday urological dilemma</article-title><source>Neurourol Urodyn</source><year>2001</year><volume>20</volume><fpage>237</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">11385690</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname><given-names>CR</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name></person-group><article-title>A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder</article-title><source>Eur Urol</source><year>2006</year><volume>49</volume><fpage>651</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16530611</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>R</given-names></name><name><surname>Ikegaki</surname><given-names>I</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name></person-group><article-title>Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors</article-title><source>Jpn J Pharmacol</source><year>1999</year><volume>79</volume><fpage>447</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">10361884</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Hosoda</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>HY</given-names></name><name><surname>Ogushi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor</article-title><source>J Urol</source><year>2005</year><volume>174</volume><fpage>370</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15947692</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurizaki</surname><given-names>Y</given-names></name><name><surname>Ishizuka</surname><given-names>O</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Ichino</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>T</given-names></name><name><surname>Igawa</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms</article-title><source>Scand J Urol Nephrol</source><year>2011</year><volume>45</volume><fpage>15</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20961266</pub-id></element-citation></ref></ref-list></back></article>